The Beauty Health Company (SKIN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company has raised its revenue and EBITDA guidance, indicating strong financial metrics. Despite a challenging macroeconomic environment, the focus on controllable growth levers and operational discipline is promising. The Q&A reveals improved churn rates and strategic targeting of new demographics, which could enhance market penetration. While there are some uncertainties, such as the lack of specifics on new products, the overall sentiment is positive, with innovative strategies in place for future growth.
Key Financial Performance
Total Revenue (Q4 2025) $82.4 million, a decrease of 1.3% year-over-year. The decline was attributed to lower system sales, though it marked an improvement from the double-digit decline in Q3.
Consumables Revenue (Q4 2025) $57.7 million, an increase of 1.7% year-over-year. This growth highlights the resilience of the recurring revenue model.
Device Revenue (Q4 2025) $24.7 million, a decrease of 7.9% year-over-year. The decline reflects pressure in the capital equipment segment due to the broader macroeconomic environment, though performance improved compared to Q3.
Adjusted Gross Margin (Q4 2025) 67.4%, an increase from 67.1% in the prior year. The improvement was driven by a favorable mix shift towards consumable revenue.
GAAP Gross Margin (Q4 2025) 64.4%, an increase from 62.7% in the prior year. The improvement was primarily driven by lower inventory-related charges and a favorable mix shift towards consumables.
Adjusted EBITDA (Q4 2025) $15 million, an increase from $9 million in the prior year, representing approximately 700 basis points of margin expansion. This improvement was driven by disciplined execution and cost management.
Net Sales (Full Year 2025) $300.8 million, a decrease from $334.3 million in 2024. The decline was primarily due to lower system sales.
Consumables Revenue (Full Year 2025) $212.7 million. This metric underscores the importance of the recurring revenue model.
Device Revenue (Full Year 2025) $88.1 million. The decline in device revenue reflects challenges in the capital equipment segment.
Adjusted EBITDA (Full Year 2025) $45.1 million, a significant increase from $12.3 million in 2024. The improvement was driven by expense discipline and sustained margin improvement.
GAAP Gross Margin (Full Year 2025) 65.3%, an increase from 54.5% in 2024. The improvement was driven by a favorable mix shift towards consumables and lower inventory-related charges.
Adjusted Gross Margin (Full Year 2025) 68%, an increase from 62% in 2024. The improvement reflects a favorable mix shift towards consumables.
Operating Cash Flows (Full Year 2025) $37 million, reflecting strong cash generation.
Cash, Cash Equivalents, and Restricted Cash (End of 2025) $232.7 million, a decrease from $370.1 million at the end of 2024. The decline was primarily due to the repurchase of convertible senior notes and debt restructuring.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Hydrafacial System: Development of a next-generation Hydrafacial system aimed at driving upgrades across the installed base and expanding market share.
SkinStylus: Focus on expanding its role in providers' practices within the growing microneedling category.
Clinically-backed boosters: Investments in a selective portfolio of boosters to increase attachment rates, improve provider economics, and expand treatment protocols.
Global Med Spa Market: The U.S. med spa market has grown from 1,600 locations in 2010 to over 13,000 today, indicating significant market expansion.
Demographic Expansion: Broader demographics, including men, Gen Z, and younger consumers, are engaging with treatments earlier.
Installed Base Utilization: Focus on improving utilization of the 36,000+ installed systems to drive consumables revenue and margin expansion.
Sales Force Excellence: Transition to a value-based selling model with structured sales plans and enhanced commercial tools.
Marketing Discipline: Refinement of Hydrafacial's positioning as a clinical-grade skin health platform and activation of underleveraged assets like SkinStylus.
Profitability Improvements: Adjusted EBITDA increased to $45.1 million in 2025, up from $12.3 million in 2024, driven by cost discipline and margin improvements.
Shift to Utilization Model: Transition from a device placement model to a device utilization model to align with market maturity and drive long-term growth.
Focus on Innovation: Targeted investments in clinically meaningful innovation, including new product development and external partnerships to broaden the product ecosystem.
Operational Discipline: Implementation of structured sales plans, enhanced analytics, and targeted marketing to stabilize and prepare for growth in 2027.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic Environment: The company is experiencing pressure in the capital equipment segment due to the broader macroeconomic environment, which has impacted device revenue and led to a decline in system sales.
Competitive Activity: Increased competitive activity has lengthened the device sales cycle, posing challenges to sales execution and market positioning.
Sales Organization Transition: The transition within the sales organization to a value-based selling model may temporarily disrupt sales performance and execution.
International Market Adjustments: Ongoing adjustments in international markets, including China, have impacted revenue and operational stability.
Underutilized Installed Base: The installed base of over 36,000 systems is underutilized, limiting the potential for consumables revenue and margin expansion.
Seasonal Dynamics: Seasonal dynamics, including typical ordering patterns and increased sales and marketing activity early in the year, contribute to revenue fluctuations, particularly in the first quarter.
Debt and Cash Flow Management: The company experienced a 37% decrease in cash, cash equivalents, and restricted cash year-over-year, primarily due to the repurchase of convertible senior notes, which could impact liquidity.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections for 2026: The company expects revenue in the range of $285 million to $305 million for the full year 2026, with a more back-half weighted cadence as execution initiatives take hold.
Adjusted EBITDA for 2026: Positive adjusted EBITDA is projected in the range of $35 million to $45 million for the full year 2026.
First Half of 2026 Performance: The first half of 2026 is expected to be modestly below the prior year due to macroeconomic pressures, competitive activity, and ongoing adjustments in international markets, including China.
Second Half of 2026 Performance: Momentum is expected to improve in the second half of 2026, positioning the company to exit the year on a stronger trajectory.
2027 Growth Expectations: The company expects to return to growth in 2027, with accelerated growth beyond that as innovation and product launches scale.
First Quarter of 2026 Guidance: Revenue is expected to be in the range of $63 million to $68 million, with positive adjusted EBITDA of $3.5 million to $5.5 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Repurchase of convertible senior notes: The company repurchased convertible senior notes during the first half of 2025. This action, along with the refinancing of the notes, significantly strengthened the company's capital structure and extended its debt maturity profile.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the company's outlook for next year despite another year of sales declines?
A:The company expects revenue to be flat year-on-year at the midpoint of guidance, normalizing for the China transition. Adjusted EBITDA is expected to be slightly below 2025 due to reinvestment in R&D for future innovation. The first half of the year is expected to be down mid-single digits, while the second half is expected to be flat. Without the APAC impact, the first half is expected to be down low single digits, and the second half is expected to show positive low single-digit growth.
Q:What are the underlying assumptions for the market environment and trends throughout the year?
A:The company assumes that consumers are still spending but are more selective, favoring treatments with clinically proven results at accessible price points. The aesthetics category has been pressured due to tight credit and longer capital spending decisions. Growth is not reliant on macro trends but on the company's execution strategy. Medical spas, which make up 70% of the U.S. business, continue to grow, while plastic surgeons are losing traction, and dermatologists remain stable. Non-invasive treatments are holding up better than invasive ones. The non-medical segment, which includes day spas and single-room estheticians, is expected to remain stable.
Q:What is the company's strategy to address churn and target new customer segments like Men and Gen Z?
A:Churn improved in Q4 2025 to 1.1% from 1.8% in Q3. The company is restructuring inside sales and customer service teams to better support smaller accounts, which are the main drivers of churn. The guide assumes churn will remain flat year-over-year, with potential upside. For new customer segments like Men and Gen Z, the company is leveraging its brand, large installed base, and razor-razor blade model to unlock potential. They are addressing specific skin health concerns and positioning Hydrafacial as part of a lifestyle routine, focusing on outcome-driven protocols and clinically validated results.
Q:What is the timeline and focus for the next-generation Hydrafacial system?
A:The next-generation Hydrafacial system is planned for launch in 2028. The focus is on creating a device that provides a compelling reason for existing providers to upgrade and new providers to join. The system will materially advance the value proposition and return on investment for providers, with features that add value, differentiate from competitors, and provide desired outcomes.
Q:What is the company's long-term outlook for sales between consumables and new device placements?
A:Currently, sales are approximately 70% consumables and 30% new devices. The company aims to return to device growth and will provide updates on targets as they progress.
Q:What is driving strong consumable sales in EMEA, and can this be replicated in other regions?
A:EMEA's strong consumable sales are driven by the launch of five new boosters in 2025, which demonstrates the power of innovation. Germany, in particular, performed exceptionally well. The company plans to replicate this success by launching clinically differentiated boosters, equipping providers with marketing tools, investing in education, and driving consumer mindshare.
Q:What is the company's guidance for Q1 2026, and is there any conservatism in the guidance philosophy?
A:Q1 2026 revenue guidance at the midpoint implies a mid-single-digit decline, primarily due to softness in the APAC region and equipment softness in the Americas. Consumables revenue is projected to be lower year-over-year due to timing of distributor orders and macro pressures. The company guides towards the midpoint and does not deliberately factor in conservatism.
Q:What is the anticipated launch cadence for boosters in 2026, and how are they performing?
A:Boosters account for about 1/5 of treatments, with revenue up 7% year-over-year in Q4 2025. The company plans to over-index on launching clinically differentiated boosters with a disciplined cadence, supported by marketing, education, and post-sales onboarding. The focus is on driving consumer mindshare and brand investment.
Q:What is the company's pricing strategy for consumables, and how does it impact utilization?
A:The company implemented a 5% price increase on consumables in Q3 2025, which was well-received with minimal pushback. Providers who understand how to prescribe boosters use roughly 3x more boosters than those who do not. The company is investing in marketing and education to improve utilization.
Q:What are the company's plans for managing OpEx and achieving cost efficiencies?
A:The company is creating shared service centers and investing in back-end system infrastructure to manage the global business effectively. G&A is expected to remain stable to slightly up, with additional reinvestment in R&D. Over the long term, the company sees opportunities to gain efficiencies and leverage fixed costs as growth returns.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about the features of the next-generation Hydrafacial system, stating only that it will materially advance the value proposition and return on investment. Additionally, they did not provide a target for the long-term sales mix between consumables and new devices, stating only that they aim to return to device growth.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Act
BeautyHealth
Hydrafacial
Section Securities
activation
area health
asset
base system
base utilization
center
combination
consumables model
credibility
demand generation
discipline rigor
economics
force excellence
foundation
health platform
hold momentum
marketing discipline
model device
model leverage
momentum trajectory
patient provider
pattern
phase
productivity base
protocol market
provider education
provider practice
role provider
stage
task
tech
technology
today consumer
treatment protocol
utilization consumables
SKIN Transcript
The Beauty Health Company (SKIN) Q4 2025 Earnings Call Transcript
Positive3-13
The company has raised its revenue and EBITDA guidance, indicating strong financial metrics. Despite a challenging macroeconomic environment, the focus on controllable growth levers and operational discipline is promising. The Q&A reveals improved churn rates and strategic targeting of new demographics, which could enhance market penetration. While there are some uncertainties, such as the lack of specifics on new products, the overall sentiment is positive, with innovative strategies in place for future growth.
The Beauty Health Company (SKIN) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call reveals positive developments: increased revenue and EBITDA guidance, successful price hikes, and promising product launches. Although device sales face challenges, consumables show growth, and stabilization efforts are underway. The company's focus on innovation and strategic pricing, coupled with a positive market response to price increases, indicates a potential stock price uplift. However, management's lack of specific guidance for 2026 and ongoing macroeconomic pressures temper expectations, suggesting a moderate positive sentiment.
The Beauty Health Company (SKIN) Q2 2025 Earnings Call Transcript
Unknown8-8
Despite exceeding Q1 revenue and EBITDA guidance, concerns about declining gross margins due to tariffs, increased R&D spending, and macroeconomic pressures, such as higher churn and ASP pressure, neutralize the positive impact. The optimistic guidance and strategic initiatives like new product launches and loyalty programs offer potential upside, but uncertainties in execution and financial health create a balanced outlook.
Earnings call transcript: Beauty Health Co Q1 2025 sees revenue growth, stock dips
Unknown5-8
The earnings call presents a mixed outlook: strong financial metrics with increased revenue and improved EBITDA, but offset by macroeconomic pressures and tariff impacts. The Q&A reveals management's optimism about product launches and market leadership, yet concerns about luxury treatment demand and tariff costs persist. Despite improved gross margins and cash position, uncertainties in China and the global market, along with unclear guidance on tariffs, temper the positive financial results. These mixed factors suggest a neutral stock price movement over the next two weeks.
SKIN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
